Obesity
Lilly Expands Obesity Drug Range Amid Safety Trials
Eli Lilly is aggressively pursuing advancements in the field of obesity treatment, accelerating the development of an oral medication option ...
Novo Nordisk’s Wegovy boosts heart health, J.P. Morgan predicts $71B GLP-1 market by 2032
The demand for Novo Nordisk’s obesity medications is surging, with production capacity being the primary limiting factor in the short ...
Novo Nordisk acquires Embark Biotech for 15 million euros in obesity deal spree
Novo Nordisk has made another move to expand its obesity portfolio, acquiring Embark Biotech for 15 million euros ($16 million) ...
Novo Nordisk’s Semaglutide Triumphs Again: A Heartfelt Victory in the Battle Against Heart Failure
In a remarkable turn of events, the pharmaceutical landscape witnesses Novo Nordisk’s semaglutide, a true star in its arsenal, claiming ...
Novo Nordisk Turns to Thermo Fisher for Production Aid with Obesity Drug Wegovy Amid Catalent Challenges
Novo Nordisk Struggles to Keep Up with High Demand for Wegovy, Enlists Thermo Fisher to Boost Production Amid soaring demand ...
Boehringer’s Obesity Drug with Dual Mechanism Ready for Phase III
Boehringer Ingelheim is forging ahead with its obesity drug candidate, survodutide, moving it into a Phase III program following promising ...
Novo Nordisk and Eli Lilly Ride Obesity and Diabetes Drugs to the Forefront in Q2 Pharmaceutical Performance
As the COVID-19 pandemic surged and waned, the biopharmaceutical industry witnessed a rollercoaster ride of revenue spikes and troughs. However, ...
How Mounjaro Boosted Eli Lilly’s Sales and Fought Obesity
As Eli Lilly’s flagship diabetes medication, Mounjaro, continues its meteoric rise in popularity and edges closer to potential approval for ...
leading obesity medication Wegovy’s ‘best-case scenario’ Novo Nordisk published cardiac results statistics
Source – Novo Nordisk Novo Nordisk has been capitalizing on the momentum generated by its weight loss drug, Wegovy, which ...
Eli Lilly’s Tirzepatide Succeeds in 2 More Late-Stage Obesity Trials Ahead of FDA Decision
Source – Eli Lilly Eli Lilly continues to gather strong evidence supporting the effectiveness of tirzepatide, its dual GIP/GLP-1 agonist, ...
Weighing the benefits and drawbacks of the newest Weight loss medication as well as their financial impact
Weight Loss Medication: Obesity rates in the United States have significantly increased since the 1980s, with a staggering 41.9% of ...
Medicare prescription coverage for obesity is supported by legislation by Novo Nordisk, Eli Lilly, and Boehringer Ingelheim
Despite the considerable excitement surrounding the potential of new and potent obesity medicines, these drugs remain inaccessible to many Americans ...
Saxenda is now in low supply as Novo Nordisk issues a supply warning till 2023
Due to a shortage of Novo Nordisk’s popular obesity medicine Wegovy, there has been a surge in demand for their ...
Novo Nordisk and Eli Lilly Drive Breakthroughs in Oral GLP-1 Treatments for Obesity at ADA Conference
Novo Nordisk and Eli Lilly showcased advancements in the development of oral GLP-1 treatments for Type II diabetes and obesity ...
Lilly’s Retatrutide Shows Promising Phase II Results By Weight Reduction in Adults with Obesity and Overweight
Source – Eli Lilly On June 26, 2023, Eli Lilly and Company announced the release of new Phase II findings ...
Pfizer Shares Progress of Clinical Development Program for GLP-1-RA in Adults with Obesity and Type II Diabetes Mellitus
Source – Pfizer On June 26, 2023, Pfizer Provides Update on Clinical Development Program for GLP-1-RA in Obesity and Type ...
Lilly’s SURMOUNT-2 Study Shows Tirzepatide Achieves Significant 15.7% Weight Reduction in Adults with Obesity and Type 2 Diabetes
Source – Eli Lilly On June 24, 2023, Eli Lilly and Company’s tirzepatide showed promising results in the SURMOUNT-2 Phase ...
Lilly’s Orforglipron Shows Promising Weight Reduction in Obesity and Overweight Patients: Phase II Findings
Source – Eli Lilly On June 23, 2023, Eli Lilly and Company announced the Phase II results for orforglipron, an ...
At the 83rd Scientific Sessions of the American Diabetes Association, Lilly will discuss fresh findings in the management of diabetes and obesity
Source – Eli Lilly On 20 June 2023 at the American Diabetes Association’s (ADA) 83rd Scientific Sessions in San Diego ...
